Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.
Vesalius Therapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Vesalius Therapeutics's investors include Flagship Pioneering.
Vesalius Therapeutics is headquartered in Cambridge, United States.
Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.
Vesalius Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vesalius Therapeutics — Funding & Investors." VCBacked, March 2, 2022, https://www.vcbacked.co/company/vesalius-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Vesalius Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/vesalius-therapeutics
{{cite web |title=Vesalius Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vesalius-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated